Clinical Trials Directory

Trials / Completed

CompletedNCT02519062

Role of FDG PET, Immune and Hypoxic Marker in NSCLC

FDG-PET, Marker Immunologici ed Ipossici in Pazienti Affetti da Carcinoma Polmonare Non a Piccole Cellule in Stadio I-III Sottoposti a Chirurgia Radicale

Status
Completed
Phase
Study type
Observational
Enrollment
130 (actual)
Sponsor
Istituto Clinico Humanitas · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a retrospective study that involves the revision of clinical, instrumental and pathologic data of an estimated cohort of maximum 130 patients with NSCLC treated with surgery with radical intent at our center.

Detailed description

This is a retrospective observation that involves the revision of clinical, instrumental and pathologic data of an estimated cohort of 130 patients with NSCLC treated with surgery with radical intent at our center. We will review FDG-PET acquired within 30 days prior to surgery and analyze its principal imaging characteristics with respect to hypoxic and immune-related markers at immunohistochemistry (IHC). These markers will be studied on tumor tissue obtained at surgery, used for diagnostic purposes and stored in paraffin.

Conditions

Interventions

TypeNameDescription
OTHERNo interventionThis is a retrospective study

Timeline

Start date
2014-12-01
Primary completion
2018-12-01
Completion
2018-12-01
First posted
2015-08-10
Last updated
2020-10-01

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT02519062. Inclusion in this directory is not an endorsement.